

Koprivnica, April 28 2026.

Podravka Group continues to grow its revenues and profitability in the first quarter of 2026

Podravka Group continued its successful performance in the first three months of 2026, with revenue growth in the Food and Pharmaceuticals segments, as well as an increase in revenue and profitability at Group level. Group revenues increased by 4.9 million euros, which is two percent higher than last year. The normalized net profit of Podravka Group in the first three months of 2026 amounts to 21 million euros and is 4.7 percent higher compared to the same period.

“The first quarter of 2026 confirms the continuity of Podravka Group’s successful operations, with revenue growth and increased profitability at Group level. I am especially pleased that, even after a very intensive period of acquiring agricultural companies and completing the strongest investment cycle in the Group’s history, we are continuing to deliver good business results and further developmental strides. In a challenging international environment, also marked by disruptions caused by the war in the Middle East, Podravka is confirming its resilience, the strength of its brands and its ability to continue growing and investing. Contributing to this are our food and pharmaceutical brands, as well as the development of the agricultural segment, which is undergoing a phase of operational and investment strengthening,” said Martina Dalić, President of the Management Board of Podravka.

“We are fully focused on further improving efficiency, investing in employees, production capacities and digital transformation, and on creating the preconditions for long-term growth and development of all business segments,” she added.

In the period from January to March 2026, the Food segment achieved 2.6 million euros, or 1.8 percent higher sales revenues compared to the same period last year, while the Pharmaceuticals segment recorded revenue growth of 2.2 million euros, or 4.9 percent. The Agri segment generated 0.3 million euros, or 0.4 percent lower operating revenues compared to the comparable period. This result was achieved amid a sharp decline in milk prices and disruptions in the live pig market due to the spread of African swine fever in Europe, as well as a different sales realization dynamic in crop farming compared with the previous year.

The growth of normalized net profit was achieved in the Food and Agri segments, while the Pharmaceuticals segment recorded a slightly lower level of normalized net profit.

In parallel with the growth of revenue and profitability, Podravka Group continued to invest in modernization and development, with capital expenditures amounting to 7.4 million euros. The largest part of the investments is directed towards further improving the efficiency and sustainability of agricultural production within the Agri segment, from the procurement of new agricultural machinery and irrigation systems to the genetic improvement of the herd, which should ensure higher yields and stronger competitiveness in the long term. At the same time, the modernization of production lines in the food business continues, as does the development of new facilities at Podravka's locations, further strengthening the brand's connection with consumers and creating the preconditions for further growth in profitability.